Domain Therapeutics is a biopharmaceutical company. It uses transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.
|Employees (est.) (Sept 2021)||79|
Domain Therapeutics total Funding
Domain Therapeutics latest funding size
Time since last funding
|2 years ago|
Domain Therapeutics investors
|Bpifrance, Seventure Partners, Idinvest Partners, Sofinnova Partners, Auriga Partners, Groupe Siparex, The Michael J. Fox Foundation, Andera Partners, Alsace création, Airfi aero, SODIV ALSACE|
Domain Therapeutics has 201 Twitter Followers. The number of followers has increased 2.4% month over month and increased 9.3% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Domain Therapeutics founded?
Domain Therapeutics was founded in 2001.
Who are Domain Therapeutics key executives?
Domain Therapeutics's key executives are Youssef L. Bennani, Pascal Neuville and Michel Ronc.
How many employees does Domain Therapeutics have?
Domain Therapeutics has 79 employees.
Who are Domain Therapeutics competitors?
Competitors of Domain Therapeutics include Redesign Science, e-therapeutics and Innoforce Pharmaceuticals.
Where is Domain Therapeutics headquarters?
Domain Therapeutics headquarters is located at Bioparc 3, 850 boulevard Sébastien Brant, Illkirch-Graffenstaden.
Where are Domain Therapeutics offices?
Domain Therapeutics has offices in Illkirch-Graffenstaden and Montréal.
How many offices does Domain Therapeutics have?
Domain Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies